Drug Trial News

RSS

Selkirk Pharma introduces ClinFAST™ to expedite fill/finish for clinical trials

Selkirk Pharma, Inc., a privately held U.S. pharmaceutical manufacturer specializing in the fill and finish of injectable drugs, including vaccines and biological therapeutics, today announced the launch of ClinFAST™, a paradigm-shifting service designed to assist clinical stage biotech and pharma companies with a rapid fill/finish process for clinical trial supplies.

13 Feb 2025

University of Michigan tests novel mechanical heart pump in clinical trial

A cardiac surgery and heart failure team at the University of Michigan implanted a novel mechanical heart pump into a patient as part of a clinical trial that will compare it to the only device currently used to treat end-stage heart failure.

12 Feb 2025

NIH clinical trial examines investigational therapy for dengue

A clinical trial supported by the National Institutes of Health (NIH) is testing an experimental treatment designed to help people suffering the effects of dengue, a mosquito-borne viral disease.

11 Feb 2025

AIM Vaccine submits mRNA RSV vaccine for FDA clinical trials

AIM Vaccine Co., Ltd., a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory syncytial virus) vaccine has recently been submitted for clinical trials to the U.S. Food and Drug Administration (FDA).

10 Feb 2025

Neoantigen vaccine sparks powerful immune defense against kidney cancer

A personalized neoantigen cancer vaccine generated strong immune responses in renal cell carcinoma patients, leading to long-lasting T cell expansion and no disease recurrence after 40 months.

6 Feb 2025

New nasal vaccine for COVID-19 set to begin clinical trial in the U.S.

A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug application from Ocugen, Inc. was approved by the Food and Drug Administration (FDA). Ocugen, a U.S.-based biotechnology company, licensed the innovative technology from WashU in 2022.

5 Feb 2025

Breakthrough personalized vaccine shows promising results in kidney cancer trial

Dana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a successful anti-cancer immune response after initiation of a personalized cancer vaccine.

5 Feb 2025

International trial aims to prevent Alzheimer’s in high-risk young adults

The first participants in an international clinical trial aimed at preventing Alzheimer's disease in young adults at high risk of the disease have been enrolled.

4 Feb 2025

Uganda launches first ever vaccine trial for Sudan Ebola virus

In a global first, Uganda's Ministry of Health, the World Health Organization (WHO) and other partners today launched a first ever vaccine trial for Ebola from the Sudan species of the virus, and at an unprecedented speed for a randomized vaccine trial in an emergency.

4 Feb 2025

NIH-supported clinical trial to test experimental treatment for dengue

A clinical trial supported by the National Institutes of Health (NIH) is testing an experimental treatment designed to help people suffering the effects of dengue, a mosquito-borne viral disease.

31 Jan 2025

Single dose IV iron shows promise in treating anemia during pregnancy

Anemia during pregnancy is a common occurrence and often due to iron deficiency. It is a global public health problem, affecting an estimated 37 percent of pregnant individuals, according to the World Health Organization.

31 Jan 2025

Three new drug regimens offer hope for drug-resistant tuberculosis

Tuberculosis remains one of the top infectious disease killers worldwide, a challenge amplified by drug-resistant forms of the disease.

29 Jan 2025

Triple therapy shows strong response in BRAF V600E mutant metastatic colorectal cancer

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy regimen, according to results from the Phase III BREAKWATER trial led by researchers at The University of Texas MD Anderson Cancer Center.

26 Jan 2025

Study reveals abelacimab’s potential to improve anticoagulation safety for AFib patients

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and efficacy. While ischemic stroke rates were slightly higher, they were not statistically significant, warranting further phase 3 trials for confirmation.

23 Jan 2025

Dapagliflozin and calorie restriction show higher remission rates in type 2 diabetes

Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much higher rates of remission compared with calorie restriction alone, finds a trial published by The BMJ today.

23 Jan 2025

Real-world effectiveness and safety of olaparib in HRD-positive BRCA wild-type ovarian cancer

Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction of poly (ADP-ribose) polymerase (PARP) inhibitors, which are now standard in the maintenance setting following first-line chemotherapy.

23 Jan 2025

New Factor XI inhibitor shows superior safety in treating atrial fibrillation

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to concerns of increased risk of bleeding complications.

22 Jan 2025

Insilico Medicine doses first patient in Phase I Trial of ISM6331 for mesothelioma

Insilico Medcine( "Insilico") , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today announced the first patient has been dosed in the global multicenter Phase I Trial of ISM6331, a novel pan-TEAD inhibitor developed from Insilico's generative chemistry engine Chemistry42, for the treatment of mesothelioma and other solid tumors.

22 Jan 2025

Study evaluates effectiveness and safety of TMF for chronic hepatitis B

Chronic hepatitis B (CHB) remains a significant global health challenge, and effective antiviral therapies are essential for long-term management.

17 Jan 2025

New clinical trial aims to extend survival for bile duct cancer patients

A new clinical trial, sponsored by UCL and UCLH, aims to extend survival for some patients with cancer in the biliary tract by treating them with therapies specifically tailored to the genetic profile of their tumor.

17 Jan 2025